We posit that combination anti-angiogenic therapy may have a strong role in improving cell-based therapy in advanced BTC, given the high amount of hypoxia/desmoplasia, VEGF expression and stromal CAFs in the tumor microenvironment of these cancers. This evidence concerns the gene VEGFA and cancer.